Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)

Study Identifier:
E05-001
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: eculizumab
Date
May 2005 - Sep 2008
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: eculizumab
Date
May 2005 - Sep 2008
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information

Protocol Summary

The purpose of this study is to evaluate the long-term safety of eculizumab in patients with transfusion dependent hemolytic PNH.

Trial Locations

Location
Status
Location
Stanford University Medical Center, Division of Hematology
Stanford, California, United States, 94305
Status
N/A
Location
Hartford Hospital, Cancer Clinical Research Office
Hartford, Connecticut, United States, 06102
Status
N/A
Location
Cleveland Clinic Florida, Department of Clinical Research
Weston, Florida, United States, 33331
Status
N/A
Location
Indianapolis University Cancer Center
Indianapolis, Indiana, United States, 46202
Status
N/A
Location
Johns Hopkins University Medical Center
Baltimore, Maryland, United States, 21205
Status
N/A
Location
National Heart, Lung, and Blood Institute, National Institutes of Health
Bethesda, Maryland, United States, 20892
Status
N/A